Scholarlink

Background <p>Breast cancer is a leading cause of mortality worldwide, and conventional treatments such as chemotherapy and radiation therapy face significant limitations including toxicity, variable efficacy, and resistance. There is a critical need for innovative strategies that offer precision targeting with fewer side effects.</p> Main body <p>Bacteriophages, traditionally recognized for their bacteriolytic activity against oncogenic bacteria, have recently emerged as promising tools in breast cancer management. Beyond their natural antibacterial role, engineered bacteriophages have been developed to act as vehicles for targeted gene delivery, drug delivery, and vaccine production. Phage display technologies enable the presentation of tumor-specific ligands, enhancing specificity and minimizing off-target effects. Additionally, phage-mediated targeting can modulate the tumor microenvironment and improve immune responses against breast cancer.</p> Conclusion <p>Bacteriophages represent a dual therapeutic strategy in breast cancer: eradication of oncogenic bacteria and precision engineering as nanocarriers for cancer therapeutics. Their unique biological properties offer a foundation for developing safer, more effective treatments that complement or even surpass conventional approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bacteriophages: unlocking a new frontier in breast cancer management by defeating oncogenic bacteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • Yasmin N. Ramadan,
  • Zainab I. Rashed,
  • Rehab Ahmed,
  • Hoda A. Salem,
  • Hanan Alshareef,
  • Eltayib Hassan Ahmad-Abakur,
  • Fawaz E. Alanazi,
  • Hassabelrasoul Elfadil,
  • Helal F. Hetta

摘要

Background

Breast cancer is a leading cause of mortality worldwide, and conventional treatments such as chemotherapy and radiation therapy face significant limitations including toxicity, variable efficacy, and resistance. There is a critical need for innovative strategies that offer precision targeting with fewer side effects.

Main body

Bacteriophages, traditionally recognized for their bacteriolytic activity against oncogenic bacteria, have recently emerged as promising tools in breast cancer management. Beyond their natural antibacterial role, engineered bacteriophages have been developed to act as vehicles for targeted gene delivery, drug delivery, and vaccine production. Phage display technologies enable the presentation of tumor-specific ligands, enhancing specificity and minimizing off-target effects. Additionally, phage-mediated targeting can modulate the tumor microenvironment and improve immune responses against breast cancer.

Conclusion

Bacteriophages represent a dual therapeutic strategy in breast cancer: eradication of oncogenic bacteria and precision engineering as nanocarriers for cancer therapeutics. Their unique biological properties offer a foundation for developing safer, more effective treatments that complement or even surpass conventional approaches.